These antibiotics can also be cheaper and easier to treat tuberculosis!

Scientists have taken an important step in designing a new antibiotic to fight resistant bacterial infections, such as tuberculosis. In the study of natural chemical biology using recombinant mouse proteins, they described these new compounds to attack previous non-targeted enzymes, which are important for building and sustaining the cell wall of bacteria. The team said that these antibiotics can also be cheaper and easier to treat tuberculosis (TB).

The treatment of MDR-TB is costly. In addition, the treatment takes a long time and do harm to human body, and it has potentially life-threatening side effects. "One of the reasons for the new study is that more than half of the antibiotics given to patients today are of the β-lactam class," said Gyanu Lamichhane, associate professor of medicine at the Johns Hopkins University School of Medicine in Baltimore. These drugs paly their role by destroying DD-transpeptidase enzyme, while this enzyme is essential for the construction and maintenance of bacterial cell walls. Without enzymes, the bacteria die quickly.

However, about 10 years ago, the researchers discovered another enzyme called LD-transpeptidase - also important for the cell wall - is an antibiotic that allows bacteria such as TB to survive. In new research - in a complex imaging system, with the help of a protein called X-ray crystallography, the team investigated the detailed molecular structure of the LD-transpeptidase extracted from various bacteria.

With knowledge about the structure of the new enzyme, the researchers then tested the molecules that might work on it. They tested new compounds from beta-lactam antibiotic subclasses that specifically bind to new enzymes. By using live bacterial cultures, they show that compounds called carbapenems block wall-building enzymes. This also suggests that CDC, called the ESKAPE pathogen, works in a group of bacteria and is considered a particular threat because of its ability to resist drug resistance.

The team also tested two carbapenems in different groups of TB-infected mice. They found that even without the use of classical tuberculosis antibiotics, new compounds - especially ibuprofen - had a better therapeutic effect on tuberculosis in mice. "Our data show that carbapenem successfully treats tuberculosis infection by attacking enzymes," said Professor Lamichhane. The team is now planning clinical trials to test the safety and efficacy of some of these new compounds. Flarebio provides good-quality recombinant proteins like recombinant Itgb1 at competitive prices.